Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer

B-type RAF (BRAF)-V600E mutations in metastatic colorectal cancer (mCRC) have been described in up to 12% of the patients. This mutation confers a bad prognostic and poor response with standard chemotherapy. Unlike the scenario for BRAF mutant melanoma, successful BRAF blockade in mCRC has emerged a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ros, Javier, Saoudi, Nadia, Baraibar, Iosune, Salva, Francesc, Tabernero, Josep, Elez, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260564/
https://www.ncbi.nlm.nih.gov/pubmed/35812780
http://dx.doi.org/10.1177/17562848221110644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260564/
https://www.ncbi.nlm.nih.gov/pubmed/35812780
http://dx.doi.org/10.1177/17562848221110644

Ejemplares similares